Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Overcoming Barriers for Latinos on Cancer Clinical Trials

In: Advancing the Science of Cancer in Latinos [Internet]. Cham (CH): Springer; 2020. Chapter 12.
.
Affiliations
Free Books & Documents
Review

Overcoming Barriers for Latinos on Cancer Clinical Trials

Ruben A. Mesa et al.
Free Books & Documents

Excerpt

Hispanics are greatly underrepresented in the large cancer and genomic databases, and by placing all Latinos into one category, these datasets do not capture the variation in cancer determinants and outcomes that exist among Latino subgroups. Part of the solution is to include more Latinos in research, which requires improving upon the historically low Latino recruitment into cancer clinical trials. Cancer clinical trials must reflect the subpopulation that is being studied in order to capture differences among ethnic groups and to make inferences that are generalizable. There are many challenges involved in enrolling patients into clinical trials and additional barriers that must be overcome to recruit a representative number of Latinos. Recruitment programs from both the Massey Cancer Center at Virginia Commonwealth University and the Mays Cancer Center at UT Health San Antonio are excellent models of program designs that enhance Hispanic accrual and address underrepresentation in clinical trials. Recommended steps to improve accrual into clinical trials are to educate physicians to better promote enrollment; build awareness among Hispanics about the role of clinical trials in improving cancer care; enhance care navigation for treatment planning including matching the right patient with the right study; develop language- and culture-appropriate educational materials; and share lessons learned among centers and investigators.

PubMed Disclaimer

References

    1. Brown RF, Cadet DL, Houlihan RH, Thomson MD, Pratt EC, Sullivan A, et al. Perceptions of participation in a phase I, II, or III clinical trial among African American patients with cancer: what do refusers say? J Oncol Pract. 2013;9(6):287–93. https://doi.org/10.1200/JOP.2013.001039. - DOI - PMC - PubMed
    1. Chalela P, Suarez L, Munoz E, Gallion KJ, Pollock BH, Weitman SD, et al. Promoting factors and barriers to participation in early phase clinical trials: patients perspectives. J Commun Med Health Educ. 2014;4(281):1000281. https://doi.org/10.4172/2161-0711.1000281. - DOI - PMC - PubMed
    1. Ramirez AG, Wildes K, Talavera G, Napoles-Springer A, Gallion K, Perez-Stable EJ. Clinical trials attitudes and practices of Latino physicians. Contemp Clin Trials. 2008;29(4):482–92. https://doi.org/10.1016/j.cct.2007.11.001. - DOI - PMC - PubMed
    1. Langford AT, Resnicow K, Dimond EP, Denicoff AM, Germain DS, McCaskill-Stevens W, et al. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer. 2014;120(6):877–84. https://doi.org/10.1002/cncr.28483. - DOI - PMC - PubMed
    1. Occa A, Morgan SE, Potter JE. Underrepresentation of Hispanics and other minorities in clinical trials: recruiters’ perspectives. J Racial Ethn Health Disparities. 2018;5(2):322–32. https://doi.org/10.1007/s40615-017-0373-x. - DOI - PubMed

LinkOut - more resources